Research Programs
We have focused our small-molecule drug discovery efforts on enzyme targets, including proteases, kinases and polymerases. We specifically direct our research efforts toward validated enzyme targets related to significant therapeutic markets and where we can identify chemistry improvements that we believe are not covered by existing patents. A key differentiator of our drug discovery and development capabilities is the degree to which we have successfully integrated potency and selectivity assays with pharmacokinetic and pharmacodynamic evaluations to identify clinical candidates. This is designed to ensure drug-like properties of our optimized lead compounds and increase the probability for successful development. We incorporate results from all of these assays to design subsequent potential drug compounds using an iterative approach. As a result, we are able to simultaneously improve multiple characteristics of our enzyme inhibitors to increase the quality of our product candidates and decrease the time required for our discovery efforts.